Search results
Showing 16 to 30 of 166 results for atrial fibrillation
Atrial fibrillation: current treatment with anticoagulation (IND128)
This indicator covers the percentage of patients who are currently treated with anticoagulation drug therapy in those patients with atrial fibrillation with a record of a CHA2DS2-VASc score of 2 or more. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM82
This indicator covers the percentage of patients with atrial fibrillation, currently treated with an anticoagulant, who have had a review in the preceding 12 months which included: assessment of stroke/VTE risk; assessment of bleeding risk; assessment of renal function, creatinine clearance, FBC and LFTs as appropriate for their anticoagulation therapy; any adverse effects related to anticoagulation; assessment of compliance; choice of anticoagulant. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM147
Evidence-based recommendations on the CoaguChek XS system for self-monitoring coagulation status in adults and children. The recommendations originally included the InRatio2 PT/INR, but this was withdrawn from the market in October 2016 and is not currently available
NICE is unable to make a recommendation on vernakalant (Brinavess) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. This is because Correvio Ltd did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA675
Atrial fibrillation: pulse rhythm assessment in people at risk (IND168)
This indicator covers the percentage of patients registered at the practice aged 65 years and over who have been diagnosed with 1 or more of the following conditions: coronary heart disease, heart failure, hypertension, diabetes, CKD, PAD, or stroke/TIA who have had a pulse rhythm assessment in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM146
Chronic heart failure in adults: diagnosis and management (NG106)
This guideline covers diagnosing and managing chronic heart failure in people aged 18 and over. It aims to improve diagnosis and treatment to increase the length and quality of life for people with heart failure.
Safe and effective management of stroke prevention in atrial fibrillation
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia1 and its prevalence is increasing. A patient with...
attached to an electrophysiologist consultant reviews referred atrial fibrillation (AF) patients in clinic. There is a...
The recent new NICE guidelines on Atrial Fibrillation suggest that the baseline prevalence for Atrial Fibrillation is...
Screening secondary care patients for atrial fibrillation: The SOS-AF service
service is called Screening and Optimising Stroke Prevention in Atrial Fibrillation (SOS-AF). All people admitted to...
Science Network (AHSN) Alliance for Atrial Fibrillation (AF) aims to reduce the number of people dying or disabled by...
Overprescribing of rivaroxaban in non-atrial fibrillation patients in primary care
prevention of stroke and systemic embolism in association with atrial fibrillation (AF) were excluded from the audit...
NICE has developed a medtech innovation briefing (MIB) on the ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation
TactiCath Quartz catheter for percutaneous radiofrequency ablation in atrial fibrillation (MIB60)
NICE has developed a medtech innovation briefing (MIB) on the TactiCath Quartz catheter for percutaneous radiofrequency ablation in atrial fibrillation
implantable cardiac monitor (ICM) diagnostic pathway for the detection of atrial fibrillation in cryptogenic stroke during the COVID-19...